 EVANSTON, Ill.--BUSINESS WIRE--Aptinyx Inc. Nasdaq: APTX, a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinsons disease and dementia with Lewy bodies. The company anticipates reporting data from this study in the second half of 2022. W 